$EWTX News

Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow

Edgewise Therapeutics Reports Improvements In Heart Drug Trial

HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price Target

Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45

RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48

Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52

Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B

Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten

Edgewise Therapeutics Q1 EPS $(0.46) Beats $(0.50) Estimate

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

The $3B Biotech With Two Shots On Goal

Edgewise Therapeutics Presents At 2026 MDA Clinical And Scientific Conference, Long-Term Data From MESA Open-Label Extension Study Of Sevasemten In Becker Muscular Dystrophy